Inactive Instrument

All News Biostage Inc Nasdaq

Equities

US09074M1036

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	Apr. 14	CI
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Harvard Apparatus Regenerative Technology : March 19, 2024 - Investor Presentation	Mar. 18	PU
Harvard Apparatus Regenerative Technology : Q4 - 2023 HBIO Quarterly Earnings Presentation	Mar. 07	PU
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Harvard Apparatus Regenerative Technology : Northland Capital Markets Institutional Investor Conference 2023	23-09-18	PU
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Harvard Apparatus Regenerative Technology : Q2 - 2023 HBIO Quarterly Earnings Presentation	23-08-08	PU
Biostage Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	23-07-19	AQ
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	23-07-18	CI
Transcript : Biostage, Inc. - Special Call	23-06-20
Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	23-06-15	PR
Biostage to Host Investor Call	23-06-13	PR
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease	23-05-31	AQ
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	23-05-31	CI
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	23-05-31	CI
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Biostage, Inc. announced that it has received $6.005802 million in funding	23-04-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Biostage Inc Nasdaq

Equities

US09074M1036

All News

Filters